Apollomics (NASDAQ:APLM – Get Free Report) had its target price lowered by stock analysts at HC Wainwright from $5.00 to $2.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 393.83% from the company’s current price.
Apollomics Price Performance
NASDAQ APLM traded up $0.00 on Wednesday, hitting $0.41. 52,564 shares of the company traded hands, compared to its average volume of 219,394. The business’s 50 day moving average price is $0.58 and its 200-day moving average price is $0.74. Apollomics has a 52-week low of $0.39 and a 52-week high of $6.45.
Hedge Funds Weigh In On Apollomics
A hedge fund recently bought a new stake in Apollomics stock. Powell Investment Advisors LLC purchased a new position in Apollomics, Inc. (NASDAQ:APLM – Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned approximately 0.15% of Apollomics at the end of the most recent quarter. Institutional investors and hedge funds own 19.13% of the company’s stock.
About Apollomics
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Featured Articles
- Five stocks we like better than Apollomics
- Canada Bond Market Holiday: How to Invest and Trade
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- 3 Warren Buffett Stocks to Buy Now
- Generac Powers Ahead on the Electrification Mega-Trend
- Are Penny Stocks a Good Fit for Your Portfolio?
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
